说的不止是动画，更是它的叛逆。 当所有品牌都在诉说年份、历史和荣耀，它却以精心策划的一场"出逃"，揭开了所有醇香背后，那段被 窖藏的、名为"等待"的真相。西凤酒15年6年陈酿出品的诚意之作《时光的诺言》，借由一支动画，讲 述一瓶名为"六六"的酒，如何在等待与挣扎中，领悟时间的终极意义。 01出逃 有一种渴望，从未像在"六六"身上表现得如此具象。 日复一日的等待，"六六"不甘心。它尝试混入队伍，在关键时刻却被无形的规则"弹回"。一次，两次， 三次……摔回原地的，不只是瓶身，还有那颗急于奔赴远方的心。 "六六"所有的"失败"，只是因为时机未到。"叛逆"，在这里并不仅是冲突情节，更是西凤酒15年6年陈 酿，为自己写下的最严苛的品格律令：必须经历至少366天的瓶储，一天不能少。这是"出厂"前，最关 键的一次淬炼。 这不仅是品牌想说的，更是在"出逃"的戏剧冲突下，叩问的一件事：当世界都在追逐即时满足，我们是 否还敢相信并践行"延迟的奖赏"？用366天，去等一瓶酒抵达它的"最佳时刻"。 这是西凤酒15年6年陈酿对品质不容妥协的信仰，也是对消费者未曾言说的厚重承诺。就像动画中那无 形的、却绝对存在的"规则"一样。它既是禁锢 ...

Group 1 - The company has officially completed its brand upgrade, changing its name to "Sleemon Healthy Sleep Technology Co., Ltd." while maintaining its stock abbreviation and code [1] - The core of the upgrade involves a substantial expansion of the company's business scope, adding technology-related services such as technical consulting and technology promotion, emphasizing a strategy focused on "technology-driven" and "healthy sleep" [3] - The company has a strong presence in sleep technology, holding 2,472 effective patents and having launched the world's first consumer-grade brain-machine interface AI mattress, attracting interest from multiple AI companies in the U.S. for potential strategic partnerships [4] Group 2 - The company's innovative products have gained recognition in the tech community, with notable endorsements from industry figures, highlighting its leading technology in smart mattress firmness adjustment [6] - The name change further solidifies the company's strategic positioning centered around technology, with a focus on converting existing technological barriers into new growth opportunities [6] - Recent trading data shows that the company received a financing buy-in of 33.81 million yuan on January 15, 2026, with a net buy of 12.17 million yuan, indicating strong investor interest [6]

工程机械是支撑国家基础设施建设与实体经济发展的关键行业，其发展水平直接反映一国制造业综合实 力。市场普遍预期，"十五五"期间，该行业将在政策驱动、技术迭代、国际化布局三大维度实现显著突 破。在此背景下，投资者不妨借助相关金融工具，便捷布局行业机遇。2026年1月19日，工程机械ETF 华夏(515970)正式发售，该产品紧密跟踪中证工程机械主题指数，旨在为投资者提供高效参与行业、分 享发展红利的便捷渠道。 具体来看，政策驱动主要指大规模设备更新、超长期特别国债等举措持续发力，加之重大工程项目推进 与县域经济发展，共同为行业需求提供稳定支撑；技术迭代，指以高端化、智能化、绿色化为核心的创 新浪潮加速推进，头部企业于关键核心技术领域突破，国产品牌竞争力显著增强，形成协同高效产业集 群发展格局；国际化布局，则是企业积极拓展全球市场，成功突破欧美高端市场壁垒，海外业务成为重 要增长引擎，国际市场份额稳步扩大。 这些积极因素已映射至资本市场。Wind数据显示，截至2026年1月7日，中证工程机械主题指数(931752) 近1年涨幅达40.74%，充分彰显行业强劲发展动力与投资价值。回溯时间线，该指数自2016年6月30 ...

戴鸿斌院长强调，成人斜视手术不仅是为了改善外观，更关乎视功能的重建。"许多成人患者因斜视出 现复视、视疲劳甚至头痛，长期如此会影响工作效率与生活质量。因此，一旦发现斜视频率增加或伴有 相关视觉症状，应及早就诊，接受专业评估。" 3岁时，小李首次接受斜视矫正手术，后因斜视复发在7岁时进行二次矫正。成年后，随着工作压力增 大，他的左眼开始出现"间隙性"外斜——每当熬夜加班、睡眠不足或长时间面对电脑，左眼便不受控制 地跑偏。这不仅严重影响外观形象，更渐渐侵蚀着他的职业自信，甚至让他对人际交往和未来规划产生 焦虑。 为了彻底摆脱这一困扰，在新疆电力系统工作的他，毅然决定返回家乡湖北武汉寻求诊治。经过多方咨 询，他了解到武汉华厦眼科医院戴鸿斌院长在复杂成人斜视矫正领域经验丰富，尤其擅长运用微创技术 实现精准矫正，手术复发率低。 "小李属于共同性内斜视，这与长期疲劳用眼导致的眼睛协调功能下降密切相关。"武汉华厦眼科戴鸿斌 院长分析道。更棘手的是，由于小李的眼部已经接受过两次手术，眼肌结构可能已有粘连、疤痕形成或 肌力失衡，这大大增加了第三次手术的难度与风险。"既往手术会改变眼部解剖结构，肌肉与周围组织 关系复杂，再次手术 ...

2026年1月，位于首都国际机场旁、北京东北方向的重要商圈地标——斯普瑞斯奥莱，于岁末年初正式 完成焕新升级，并对外宣布将全面迈向"年轻力生活方式地标与微度假型奥莱综合体"的新定位。 一次全方位焕新升级：从"购物场"到"生活场" 本轮重装，围绕"新空间、新品牌、新体验"三个维度展开： 空间重构方面，斯普瑞斯充分发挥其开放式街区的基底优势，优化了整体动线与场内微循环，新增多个 景观停留点与市集式休闲区，打造"可逛、可停、可社交"的自在节奏。配合跨年节点上线的"雪境极光 主题艺术装置"，融合光影与自然景观，成为冬季热点打卡地。 此次升级不仅是一次空间重构，更是对消费体验、场景营造、品牌矩阵和服务系统的全面进阶，标志着 斯普瑞斯奥特莱斯正从北京奥莱单一折扣零售，走向融合生活美学、社交休闲与体验价值的新阶段。 品牌升级方面，项目引入多位重量级品牌强化"轻奢+先锋"定位。例如：Jil Sander朝阳首店：以极简风 格重塑街区审美；GIADA、MOOSE KNUCKLES等中高端服饰品牌，丰富不同客层穿搭需求；三层 MINISO旗舰店也同步落地，覆盖亲子、家庭、潮流客群生活场景。 配套服务再升级：细节处见温度 围绕"更 ...

Core Insights - The company has made significant progress in its phase change energy storage (PCM) business within the AI data center application sector, contributing to China's dual carbon goals by providing a clean heating system that utilizes waste heat from data centers [1][2] Group 1: Project Overview - The Huailai project, a collaboration with Environmental Process Systems Limited and Tsinghua University, is China's first AI data center waste heat recovery demonstration project [2] - The core breakthrough of the project lies in the company's self-developed PCM technology, which achieves a 60% energy saving rate and has received multiple invention patents [2] - The project can provide over 75,000 GJ of heat annually to surrounding communities, equivalent to approximately 20.83 million kWh, while reducing greenhouse gas emissions by over 4,000 tons of CO2 [2] Group 2: Commercialization and Market Potential - The Huailai project has achieved break-even within a year of operation and serves as a model for replicating waste heat recovery solutions across various data center regions [3] - The company is also initiating a liquid-cooled data center demonstration project in Karamay, aiming to expand the application of PCM technology in the data center sector [3] - The rapid expansion of China's data center market, projected to reach around 450 operational data centers by October 2025, along with supportive government policies, creates a vast market opportunity for the company's waste heat recovery business [3] Group 3: Technological Strength and Recognition - The company has been recognized as a national-level "Little Giant" enterprise and has received various awards, including green factory certification [4] - It holds 45 core patents and has participated in the formulation of multiple national and industry standards, providing authoritative technical support for project implementation and industry development [4] - The CEO expressed confidence in the future development of the PCM business, emphasizing the integration of cutting-edge technology with market resources [4]

Group 1 - The core viewpoint of the article highlights that Junshi Biosciences has been recognized as a future unicorn in the biotechnology sector, particularly for its innovative cell therapy and drug development in the field of solid tumors [1] - The "2025 Future Unicorn" list, published by Chuangyebang, serves as an important indicator of the evolution of China's innovation landscape, with a focus on long-term growth logic [1] - The selected companies, including Junshi Biosciences, were evaluated based on five core dimensions: founding team, technological barriers, commercialization capability, capital attractiveness, and growth momentum [1] Group 2 - Junshi Biosciences has centered its core strategy around TIL therapy, aiming to transition this disruptive cell therapy from "efficacy" to "practicality" [2] - The company has over ten research pipelines, including the world's first natural TIL therapy GC101, which is currently in critical Phase II clinical trials, and the innovative non-viral vector gene-modified TIL therapy GC203 in Phase I clinical trials [2] - These therapies have shown excellent clinical efficacy across various advanced solid tumors, with some patients achieving complete tumor clearance and maintaining no evidence of disease for over four years [2] Group 3 - Junshi Biosciences is advancing its industrialization efforts with a new TIL cell industrialization base in Shanghai, covering over 16,000 square meters, which includes production, quality, data, and operational centers [3] - The company completed a C-round financing of 137 million yuan, attracting investment from specialized institutions in the life sciences sector, indicating strong capital attractiveness [3] - The current investment climate is more pragmatic, with a focus on cost and complexity, which aligns with Junshi Biosciences' efforts to tackle challenges in cell therapy [3] Group 4 - The recognition of Junshi Biosciences amidst the AI and hardware trends of 2025 underscores the significance of companies dedicated to cell therapy [4]

Core Insights - VIKPRO is advancing its full-chain scientific system strategy through deep R&D collaboration with Düsseldorf University and guidance from biopharmaceutical professor Nicole, marking a significant step in integrating academia and industry to enhance the nutrition sector with cutting-edge academic results [1] Group 1: Technological Innovations - VIKPRO has successfully developed and applied a unique cell-level phospholipid delivery technology that overcomes traditional supplement absorption limitations, enhancing the bioavailability and targeted efficacy of core nutrients [1] - The collaboration with Professor Nicole emphasizes the practical application of scientific research in providing tangible health support [1] Group 2: Quality Control and Supply Chain - VIKPRO has established a global supply chain system that ensures a quality control loop covering raw materials, production, and end-product testing, partnering with top international suppliers like Italy's Indena to guarantee the purity and stability of active ingredients [3] - The production process adheres to FSSC and GMP standards, executed by leading global factories such as Germany's HKS, ensuring precision and traceability throughout production [3] Group 3: Transparency and Verification - VIKPRO has introduced independent third-party testing through organizations like ORIVO to establish a verification mechanism for its products, enhancing trust between the brand and consumers [5] - The core product, krill oil, has passed rigorous testing for five consecutive years, achieving zero-defect quality certification, which reinforces the value of the full-chain scientific control system [5] Group 4: Product Offerings - VIKPRO has launched a series of targeted nutritional products based on the cell-level phospholipid delivery technology, including formulations for heart health (reduced coenzyme PQQ), lung health (quercetin), and liver health (silymarin) [7] - The company aims to redefine the credibility of nutritional products through comprehensive scientific management, emphasizing that the future of the health industry relies on science and verifiable commitments [7]

Core Viewpoint - The story of the Yongzhou team, a grassroots football team that achieved an unexpected championship, resonates widely, showcasing the power of perseverance and hard work [1][3]. Group 1: Company Actions - Dr. Hu Jiaming, General Manager of Beion Intelligent, personally awarded the Yongzhou football team 200,000 yuan as a recognition of their efforts and to foster a connection between Suzhou and Yongzhou [1][5]. - The company emphasizes its commitment to positive values by celebrating the dedication and hard work of individuals [5][7]. Group 2: Team's Journey - The Yongzhou team's path to victory was marked by significant hardships, with many players being high school students balancing academics and training on a makeshift field [3][6]. - The head coach, Huang Churu, earned a modest salary of 2,700 yuan per month and often had to borrow money to support the team's expenses, highlighting the team's struggle and determination [3][6]. Group 3: Community Engagement - Dr. Hu's decision to personally deliver the award and gifts to the team reflects a deeper connection and warmth in the company's philanthropic efforts [9]. - The collaboration with the Round融 Plaza to support the Yongzhou team included waiving advertising fees, demonstrating the collective effort to promote grassroots sports [11]. Group 4: Future Aspirations - The initiative aims to strengthen the bond between Suzhou and Yongzhou, encouraging more attention to grassroots sports development [13]. - Beion Intelligent's commitment extends beyond technological prowess to include empathy and social responsibility, aiming to spread positive energy while safeguarding user health [13].

2026年1月11日，ACCESS ASIA BD Forum @JPM2026在美国旧金山洲际酒店圆满落幕。本次论坛汇聚 了来自全球数十家跨国药企、生物科技公司及研发服务组织的决策者与科学家，共同围绕亚洲尤其是中 国在全球生物医药创新与交易中的战略角色展开深度对话。作为特邀赞助方及演讲嘉宾，美迪西在本次 论坛中全方位展示了其作为药物研发一体化合作伙伴的赋能能力，并与全球行业领袖共议合作前景。 会议上，美迪西药物发现及药学研究事业部总裁段茂圣博士进行题为《中国CRO驱动下的创新生态如 何孵化资产并推动全球交易》的主题演讲，他指出，中国CRO行业已逐步实现从"服务提供者"到"创新 生态共建者"的战略转型。依托覆盖药物发现、药学研究及临床前研究的全链条一站式研发服务平台， 美迪西持续推动国内外创新药项目的高效进展，显著缩短研发周期，并为全球许可引进(license-in)与对 外授权(license-out)提供关键技术支持。段博士结合多项合作案例进一步阐明，中国CRO已在复杂靶点 验证、差异化分子设计及中美双报策略等方面发挥着日益重要的行业推动作用。 此外，美迪西美国公司总裁林庆聪博士主持了题为《从交易到全球舞 ...